Express Scripts (Evernorth / Cigna) Express Scripts, rebranded as Evernorth Health Services following Cignas $67 billion acquisition in 2018, is the largest standalone PBM operation by prescription volume
Physicians, employers and investors are watching closely as the market grows, supply ebbs and flows and new research emerges
The BBB-crossing ability of liraglutide and lixisenatide has been successfully demonstrated, and they subsequently activate GLP-1 receptors in the brain
2024 FDA Developments Several important FAA and FDA actions occurred in 2024: In January 2024, tirzepatide (Zepbound, Mounjanaro) was added to the FAAs Conditionally Acceptable Weight Loss Medications category, but medical certification required Special Issuance
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Skin laxity is a common response to rapid fat loss, and it often requires a different approach than weight loss alone